Other acute kidney failure
Methodology & AI Transparency ⓘ
Other acute kidney failure Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Chronic Kidney Disease & Electrolytes practice, Other acute kidney failure (ICD-10 N17.8) is stratified through serial eGFR (creatinine in Other acute kidney failure (N17.8: + cystatin C)), pairing targeted symptom control with longitudinal eGFR (Creatinine + in Other acute kidney failure (N17.8: Cystatin C)) surveillance.
- 2 Real-world patient consensus: Mapped to Chronic Kidney Disease & Electrolytes under ICD-10-CM N17.8 for Other acute kidney failure clinical workups.
- 3 Typical cash cost range: Primary evaluation for Other acute kidney failure incorporates serial eGFR (creatinine in Other acute kidney failure (N17.8: + cystatin C)) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Other acute kidney failure: maintaining Serum Potassium, Bicarbonate in Other acute kidney failure (N17.8: & Phosphorus) within K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N17.8).
Ask our AI Specialists anything about Other acute kidney failure
What Is Other acute kidney failure?
Within Chronic Kidney Disease & Electrolytes practice, Other acute kidney failure (ICD-10 N17.8) is stratified through serial eGFR (creatinine in Other acute kidney failure (N17.8: + cystatin C)), pairing targeted symptom control with longitudinal eGFR (Creatinine + in Other acute kidney failure (N17.8: Cystatin C)) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Other acute kidney failure (code N17.8) is podocyte barrier injury [Other acute kidney failure N17.8], which Chronic Kidney Disease & Electrolytes clinicians address while surveilling Serum Potassium, Bicarbonate in Other acute kidney failure (N17.8: & Phosphorus) (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N17.8)).
Common Symptoms & Clinical Signs
- • Presentation of Other acute kidney failure (N17.8): fatigue, muscle cramps, in Other acute kidney failure (N17.8: metallic taste, or)
- • Secondary Other acute kidney failure clinical sign: changes in urine in Other acute kidney failure (N17.8: output volume, nocturnal)
- • Symptom flares in Other acute kidney failure correlating with Serum Potassium, Bicarbonate in Other acute kidney failure (N17.8: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N17.8)
- • Functional kidney & renal impact requiring serial eGFR (creatinine in Other acute kidney failure (N17.8: + cystatin C)) evaluation (N17.8)
Other acute kidney failure Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N17.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Other acute kidney failure (N17.8: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N17.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Other acute kidney failure (N17.8: Cystatin C)) | >= 90 mL/min/1.73m2 (N17.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Other acute kidney failure (N17.8: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N17.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other acute kidney failure
Treatment selection for Other acute kidney failure depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other acute kidney failure)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other acute kidney failure Patient Community & “People Like Me” Threads
Filter Other acute kidney failure community threads and patient logs by age, biological sex, dosage, and treatment duration.